Pharmacological Countermeasures for Space Motion Sickness
Joint Agency Name:
PI Name:
Dornhoffer, John
PI Phone:
501-686-5016
PI Email:
dornhofferjohnl@uams.edu
Fax:
501-686-8029
PI Organization Type:
UNIVERSITY
Organization Name:
University of Arkansas for Medical Sciences
PI Address 1:
4301 West Markham
PI Address 2:
MS-543
City:
Little Rock
State:
AR
Zip Code:
72205
Congressional District:
2
Comments:
Project Type:
GROUND
Solicitation:
NSBRI
Start Date:
03/01/2001
End Date:
06/30/2003
No. of Post Docs:
1
No. of PHD Degree:
No. of Phd Students:
0
No. of MS Degree:
No. of MS Students:
1
No. of BS Degree:
No. of BS Students:
1
Monitoring Center:
NSBRI
Contact Monitor:
Contact Phone:
Contact Email:
Nag No.:
None
Former PI Name:
Performance Goal No.:
Performance Goal Text:
Task Description:
Aim 1 will determine the effects of drug countermeasures currently used to treat the vertiginous patient (lorazepam, meclizine, promethazine, scopolamine), in alleviating motion sickness induced by vestibular stimulation with a rotary chair. Aim 2 will determine the effects of these countermeasures on cognitive performance using an operant Test Battery to assess time perception, short-term memory, and learning, and measurment of the P50 potential to assess any deficits in senory gating. Aim 3 will use 3D oculography and unilateral otolith testing to determine the extent of correlation between vestibular dysfuntion induced by the roatry chair and unloading of otolithic organs due to 0G.
Task Objective:
Task Significance:
Task Progress:
We have shown that only scopolamine effected a statistically significant mean change in duration of rotation compared to placebo (p<0.008); scopolamine decreased the sensory gating deficit induced by rotation; scopolamine had one of the best cognitive profiles based on the OTB; and scopolamine exclusively affected the otolith organs (utricular system)
We have shown that overstimulation of the semicircular canals by rotation leads to decreased habituation to repetitive stimuli, as measured by the midlatency auditory evoked P50 potential, which may be at the root of a sensory gating deficit (an inability to appraise and filter out unwanted stimuli) present during SMS. In terms of alleviating the symptoms of rotation and the induced sensory gating deficit, our data in 72 subjects indicated scopolamine to be the countermeasure of choice. Scopolamine was the only countermeasure to effect a statistically significant mean change in duration of rotation compared to placebo (p<0.008), with >40% increase in rotation time. Results with promethazine, the current pharmacologic treatment for SMS, were not statistically significant, and meclizine and lorazepam were no more effective than placebo. Scopolamine by itself did not affect amplitude or habituation of P50 potential measures, suggesting that, at the dose used, scopolamine did not dysregulate RAS function to a significant level. However, scopolamine did lead to a lower decrease in habituation after rotation (~22%); in other words, scopolamine decreased the sensory gating deficit induced by rotation. Although this decrease was numerical and not statistically significant, it is indicative of a trend by scopolamine toward amelioration of the sensory gating deficit induced by rotation. The Operant Test Battery (OTB) indicated the Delayed Matching-to-Sample (DMTS) task, or short-term memory and attention task, to be the most sensitive measure of cognitive performance. The DMTS indicated SMS by itself had no discernible effects on accuracy or response rate and that, at the doses employed, the rank order of drugs with the best cognitive profiles are meclizine > scopolamine > promethazine > lorazepam. Work performed by our co-investigators at the Vestibular Function Laboratory in Antwerp using 3D oculography and unilateral centrifugation for otolith testing confirmed the ability of our paradigm to accurately assess the effects of countermeasures on the vestibular apparatus, from which the sensation of SMS may originate. These studies showed that the different components of the vestibular system (the semicircular canals vs. the otolith organs) react differently to the countermeasures and that scopolamine exclusively affected the utricular response, indicating a possible mechanism of action for scopolamine via a direct effect on the utricular system. The distribution of spin time frequencies among our study subject population (N=75) demonstrated that, in terms of the ability of our study subjects to tolerate induced SMS, the population had significant outliers. The majority of the study population exhibited a fairly low tolerance for induced SMS; however, there was a group of outliers who could spin significantly longer, appearing to have a predisposition to SMS tolerance. This novel finding, combined with results of off-axis rotation (see below), has been proposed for further examination as we study means of screening for SMS susceptibility and subsequent prophylaxis. As an extension of our NSBRI study, we attempted to assess the otolith organs using a new clinical paradigm involving off-axis rotation and measurement of the subjective visual vertical (SVV), the ability of an individual in darkness to adjust a luminous line to true vertical while at rest and during rotation. Clinical assessment of otolith organs is important to space medicine research due to the involvement of the utricle and saccule in SMS. Our objective was to assess otolith function in subjects with no vestibular complaints and in subjects with unilateral labyrinthine hypofunction. Subjects with no vestibular anomalies were able to set the SVV very close to vertical. However, certain subjects showed a mild asymmetry (vestibular dominance) of the otolith organs during on-axis rotation that was further accentuated during off-axis rotation. In the vestibular patients, the SVV deviated significantly toward the side of the lesion. Some subjects with dominant otolith organs were able to spin in the chair two and a half to three times longer than those without ear dominance, indicating less susceptibility to motion sickness. By screening for ear dominance using the SVV/rotational paradigm, pre-flight medication or compensation behaviors could be instituted in those individuals with an indicated susceptibility to SMS.
Earth Benefits:
This study addressed one of the main exploration-mission risk areas set forth by NASA in the Critical Path Roadmap (Impaired cognitive and/or physical performance due to motion sickness symptoms or treatments, especially during/after G-level changes [Risk Type III, Risk Rank 3]) and had a countermeasure readiness level of 6. We have addressed critical question 9.12: How effective are other drugs in providing fast relief in mission critical situations and does the drug have unacceptable side effects, particularly the short term effects on cognitive function? In addition, through the completion of this study, we have standardized measures of oculomotor function, postural stability, and cognitive performance. These standards are crucial for establishing the effectiveness and quantifying the side effects of potential drug countermeasures.
During our 2-year grant period, we have obtained salient findings in completion of the objectives of the original proposal. The results of our study have clearly indicated scopolamine to be the countermeasure of choice, leading to an NSBRI renewal proposal that will investigate optimization of the dose and delivery of this countermeasure. Thus, our renewal focuses on optimizing drug delivery parameters for scopolamine, testing potential combination therapies, and examining the feasibility of scopolamine as rescue therapy. The proposed experiments are crucial for addressing one of the key impediments to human spaceflight: namely, the need to retain cognitive function while treating SMS. Our studies should yield optimal therapy for SMS that will allow astronauts to avoid the nausea, vomiting, and dizziness of SMS while allowing them to meet the attentional, cognitive, and physical requirements of spaceflight. Our proposed study addresses one of the main exploration-mission risk areas set forth by NASA in the Critical Path Roadmap (Risk #35): Impaired cognitive and/or physical performance due to motion sickness symptoms or treatments. It represents a countermeasure readiness level of 6-7. The critical questions this proposed study would address are: How effective are other drugs in providing fast relief in mission critical situations? Does the drug have unacceptable side effects, particularly the short term effects on cognitive function? (9.12) What is the physiological basis of space motion sickness? (9.26) Because it is a clinical study, our results should be rapidly adaptable to space-based research trials.
If our off-axis work reveals a correlation between inner ear dominance and resistance to SMS, future research will also focus on developing a reliable screening paradigm for astronauts using off-axis rotation. Thus, the SVV/rotational paradigm could be used to determine those individuals who would be most susceptible to SMS, and they would receive scopolamine pre-flight.
NSCORT Background/History:
Flight Program:
Flight Assignment:
COI Name:
Garcia-Rill, Edgar
COI Institution:
UAMS
COI Name:
Paule, Merle
COI Institution:
National Center for Toxicological Research
COI Name:
Van de Heyning, Paul
COI Institution:
University Hosptial of Antwerp
Bibliography Type:
Description: (Last Updated: 02/27/2004)
Presentation
Floris Wuyts. "New techniques in vestibular assessment" The 11th British Academic Conference in Otolaryngology. Birmingham, UK, 2-5 July, 2003
Jul-2003
Abstracts for Journals and Proceedings
Paule, MG, Chelonis JJ, Blake DJ, Dornhoffer JL. "Effects of Induced Motion Sickness and/or Drug Countermeasures on Working Memory in Humans" Accepted abstract, Society for Neuroscience 2003 Annual Meeting,
New Orleans, Louisiana, Nov-2003
Abstracts for Journals and Proceedings
Griet Pauwels, Mieke Hoppenbrouwers, John Dornhoffer, Paul Van de Heyning, Floris L. Wuyts. "Specific Space Motion Sickness Related Drugs Affect Only the Horizontal Semi Circular Canal Function But Not the Utricular Function" Association for Research in Otolaryngology Midwinter Meeting
Daytona Beach, Florida, Feb-2003
Abstracts for Journals and Proceedings
Dornhoffer J, Garcia-Rill E, Paule M, Van De Heyning P, et al. "Countermeasures for Space Motion Sickness" Presented at the Bioastronautics Investigators Workshop,
Galveston, Texas, Jan-2003
Abstracts for Journals and Proceedings
F. L. Wuyts, G. Pauwels, M. Hoppenbrouwers, J. Dornhoffer, P. Van de Heyning "Pharmaceutical countermeasures for space motion sickness. The Role of the Vestibular Organs in the Exploration of Space." A post-meeting satellite of the XXII Bárány Society
Portland, Oregon, Oct-2002
Articles in Peer-reviewed Journals
Dornhoffer JL, Mamiya N, Bray P, Skinner RD, Garcia-Rill E. "Effects of Rotation on the sleep state-dependent midlatency auditory evoked P50 potential in the human" Journal of Vestibular Research (in press), 2003. , Jan-2003
Articles in Peer-reviewed Journals
Homma Y, Homma Y, Teneud L, Skinner RD, Dornhoffer J, Williams DK, Garcia-Rill E. "Effects of rotation on the P13 mid-latency auditory evoked potential in rat" Journal of Vestibular Research 2003;12:205-209. , Jan-2003
Abstracts for Journals and Proceedings
Paule, MG, Chelonis JJ, Blake DJ, Dornhoffer JL. "Effects of Induced Motion Sickness and/or Drug Countermeasures on Working Memory in Humans" Accepted abstract, Society for Neuroscience 2003 Annual Meeting,